Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions. Issue 10 (25th August 2020)

• Record Type: Journal Article
• Authors: Porter, Amy C; Aubrecht, Jiri; Birch, Chandler; Braun, Jonathan; Cuff, Carolyn; Dasgupta, Suryasarathi; Gale, Jeremy D; Hinton, Robert; Hoffmann, Steven C; Honig, Gerard; Linggi, Bryan; Schito, Marco; Casteele, Niels Vande; Sauer, John-Michael
• Is Part Of: Inflammatory bowel diseases. Volume 26:Issue 10(2020)
• Page Start: 1498
• Page End: 1508
• Publication Date: 2020-08-25
• Subjects: Crohn's disease -- inflammatory bowel disease -- ulcerative colitis -- biomarker -- biomarker qualification -- regulatory science; Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izaa215
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract: Background: Currently, 2 coprimary end points are used by health authorities to determine the effectiveness of therapeutic interventions in patients with Crohn's disease (CD): symptomatic remission (patient-reported outcome assessment) and endoscopic remission (ileocolonoscopy). However, there is lack of accepted biomarkers to facilitate regulatory decision-making in the development of novel therapeutics for the treatment of CD. Methods: With support from the Helmsley Charitable Trust, Critical Path Institute formed the Crohn's Disease Biomarkers preconsortium (CDBpC) with members from the pharmaceutical industry, academia, and nonprofit organizations to evaluate the CD biomarker landscape. Biomarkers were evaluated based on biological relevance, availability of biomarker assays, and clinical validation data. Results: The CDBpC identified the most critical need as pharmacodynamic/response biomarkers to monitor disease activity in response to therapeutic intervention. Fecal calprotectin (FC) and serum C-reactive protein (CRP) were identified as biomarkers ready for the regulatory qualification process. A number of exploratory biomarkers and potential panels of these biomarkers was also identified for additional development. Given the different factors involved in CD and disease progression, a combination of biomarkers, including inflammatory, tissue injury, genetic, and microbiome-associated biomarkers, will likely have the most utility. Conclusions: The primary focus of the Inflammatory Bowel Disease Regulatory Science Consortium will be development of exploratory biomarkers and the qualification of FC and CRP for IBD. The Inflammatory Bowel Disease Regulatory Science Consortium, focused on tools to support IBD drug development, will operate in the precompetitive space to share data, biological samples for biomarker testing, and assay information for novel biomarkers. Abstract : There is a lack of biomarkers to facilitate regulatory decision-making in the drug development process for CD therapeutics. Authors have conducted an evaluation of potential biomarkers and plan to launch a consortium to qualify novel CD biomarkers.